Abstract:Disulfiram (DSF), an FDA-approved drug for treating alcoholism, has been verified with Cu2+-dependent anticancer activity by forming Cu(DTC)2, the complex of one of its metabolites diethyldithiocarbamate (DTC) and Cu2+. Nevertheless, the antitumor effect is limited by insufficient Cu(DTC)2 formation in suit and off-target system toxicity. Herein, we developed a fibroblast activation protein α (FAPα) activatable nanoagent (HfD-HID-Cu) for co-delivery of DTC polymeric prodrug and exogenous Cu2+ to achieve enhanced cancer-specific therapy and activatable in situ fluorescence imaging meanwhile. HfD-HID-Cu was simply constructed through the co-assembly of the DTC polymeric prodrug (HA-fap-DTC) and the copper-loaded IR808-conjugated polymer (HA-IR-DPA-Cu), which could serve as the "OFF-to-ON" switch for chemotherapy and fluorescence. With the high expression of FAPα in tumor tissues, HA-fap-DTC could be activated specifically to release DTC, while maintaining inactive in normal tissues. The liberated DTC within tumor tissues could contend for Cu2+ from HA-IR-DPA-Cu, resulting in the formation of highly cytotoxic Cu(DTC)2in situ for chemotherapy, concomitant with the fluorescence recovery of cyanine dye for tumor imaging. This work provides an effective strategy for co-delivery of DTC prodrug and Cu2+ for tumor theranostic with improved selectivity and minimal side effects. STATEMENT OF SIGNIFICANCE: DSF-based antitumor therapy is highly dependent on Cu2+. However, the non-synchronous distribution of DSF/DTC and Cu2+ in tumor tissues attenuates the antitumor efficacy. The insufficient Cu(DTC)2 formation in suit and off-target distribution greatly limit the anti-tumor application. This study provides a nanoagent for co-delivery of DTC polymeric prodrug and Cu2+ by simple co-assembly to achieve their synchronous tumor distribution. It can be selectively activated by FAPα, forming cytotoxic Cu(DTC)2in suit for tumor-specific chemotherapy and reducing the systemic toxicity. In addition to chemotherapy, the nanoagent can emit fluorescence under the sequential triggering of FAPα and released DTC for tumor imaging. Overall, this study renders a promising strategy for improved Cu(DTC)2-based antitumor therapy and imaging.

A new modality of anti-cancer drug: Ferritin-drug conjugates.

Ferritin in cancer therapy: A pleiotropic tumoraffin nanocage‐based transport

Ferritin nanocage with intrinsically disordered proteins and affibody: A platform for tumor targeting with extended pharmacokinetics

H-Ferritin-Nanocaged Doxorubicin Nanoparticles Specifically Target And Kill Tumors With A Single-Dose Injection

Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy

RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors

A New Age of Drug Delivery: A Comparative Perspective of Ferritin-Drug Conjugates (FDCs) and Antibody-Drug Conjugates (ADCs)

Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer.

Transferrin-mediated fullerenes nanoparticles as Fe(2+)-dependent drug vehicles for synergistic anti-tumor efficacy

Self-assembly of Folic Acid Dextran Conjugates for Cancer Chemotherapy

Heat Sensitive E-helix Cut Ferritin Nanocages for Facile and High-Efficiency Loading of Doxorubicin.

Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting

Ferritin – a multifaceted protein scaffold for biotherapeutics

Ferritin Nanocaged Doxorubicin Potentiates Chemo‐Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death

A fibroblast activation protein α-activatable nanoagent co-delivering diethyldithiocarbamate and copper for tumor therapy and imaging

Nanobody-Ferritin Conjugate for Targeted Photodynamic Therapy

Ferrocene-conjugated polymeric platform via amide bond formation facilitates enhanced in situ fenton reaction and robust immune responses in combination with toll-like receptor 7/8 agonist

Tetralysine Modified H-chain Apoferritin Mediated Nucleus Delivery of Chemotherapy Drugs Synchronized with Passive Diffusion

Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, Β-Cyclodextrin-based Drug Complexes for Cancer Treatment.

Potential of Ferritin-Based Platforms for Tumor Immunotherapy

Hydroxyethyl Starch-Folic Acid Conjugates Stabilized Theranostic Nanoparticles for Cancer Therapy.